Top Stock Reports for Apple, Eli Lilly & Visa

Monday, October 13, 2025

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Eli Lilly and Co. (LLY) and Visa Inc. (V). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Ahead of Wall Street

The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens, attempting to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.

You can read today's AWS here >>> Pre-markets Filling Gaps to Start New Trading Week

Today's Featured Research Reports

Apple’s shares have outperformed the Zacks Computer - Micro Computers industry over the past year (+7.2% vs. +6.6%). The company is benefiting from strong growth in Services revenues. AAPL now has more than 1 billion paid subscribers across its Services portfolio. Both paid accounts and paid subscriptions grew double digits year over year in third-quarter fiscal 2025. 

Apple TV+ viewership soared double-digit year over year. Expanding capabilities of AI Intelligence is noteworthy. Apple expects the September quarter’s (fourth-quarter fiscal 2025) net sales to grow mid to high single digits on a year-over-year basis. AAPL expects the Services year-over-year growth rate to be similar to that of the June quarter.

However, gross margin is expected to be 46-47% in the fourth quarter of fiscal 2025, including a tariff impact of $1.1 billion. Increasing regulatory headwinds and tariffs are a concern for investors.

(You can read the full research report on Apple here >>>)

Shares of Eli Lilly have gained +7.8% over the year-to-date period against the Zacks Large Cap Pharmaceuticals industry’s gain of +8.5%. Demand for the company’s popular GLP-1 drugs, Mounjaro and Zepbound, remains strong, making them the company’s key top-line drivers. Launches of these drugs in new international markets and improved U.S. supply from ramped-up production led to strong sales in the first half of 2025. Lilly’s other new drugs, like Kisunla, Omvoh and Jaypirca, are also contributing to its top-line growth. 

However, data from phase III studies on its weight-loss pill, orforglipron, was mixed. Declining sales of Trulicity, rising pricing pressure on some drugs and potential competition in the GLP-1 diabetes/obesity market are some top-line headwinds. Estimates have declined slightly ahead of Q3 results. Lilly has a mixed record of earnings surprises in recent quarters.

(You can read the full research report on Eli Lilly here >>>)

Visa’s shares have outperformed the Zacks Financial Transaction Services industry over the year-to-date period (+10.2% vs. -6%). The company’s strong market position is underpinned by consistent volume-driven growth, acquisitions and technological leadership in digital payments. Expansion in cross-border volumes, rising transactions and investments in AI and stablecoin infrastructure enhance its future prospects. 

A robust financial position with ample liquidity and shareholder returns further supports long-term growth. However, it faces rising client incentives and expenses, which can weigh on margins. Regulatory pressures and potential legislative changes pose additional risks to its fee structure. 

While declining cash volumes align with its digital strategy, regional softness warrants monitoring. Moreover, Visa’s premium valuation suggests limited near-term upside. As such, the stock warrants a cautious stance.

(You can read the full research report on Visa here >>>)

Other noteworthy reports we are featuring today include Merck & Co., Inc. (MRK), TotalEnergies SE (TTE) and Automatic Data Processing, Inc. (ADP).

Mark Vickery
Senior Editor

Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>

Today's Must Read

Strong Services to Aid Apple (AAPL) Amid Tariff Headwinds

Lilly (LLY) New Drugs to Drive Sales Growth Amid Rising Competition

Visa (V) Rides On Cross-Border Volume Growth, Expenses High

Featured Reports

Keytruda Drives Merck (MRK) Sales Amid Gardasil Issues
Keytruda and new products have been driving Merck's sales. However, the Zacks analyst is concerned about declining sales of Gardasil and Keytruda's upcoming loss of exclusivity in 2028.

Expanding LNG & Clean Energy Assets Aid TotalEnergies (TTE)
Per the Zacks analyst TotalEnergies' presence in entire LNG value chain and expansion of clean energy generation through joint venture and acquisition will boost its performance.

Transformation Initiatives Aid ADP, Escalating Expenses Hurt
The Zacks analyst is positive about ADP's transformation initiatives that are helping the company to innovate, improve operations and expand margins. Rising expenses remain a concern.

Ubiquiti (UI) Rides on Healthy Demand, Product Innovation
Per the Zacks analyst, growing deployment of IoT devices across industries will likely drive Ubiquiti's prospects. Strong focus on innovation is a positive.

Strong Demand And Bookings Boost Carnival's (CCL) Prospects
Per the Zacks analyst, Carnival benefits from strong demand, increased booking volumes, and the destination strategy. Also, strong onboard revenue trends bode well.

Inside Sales Surge Fuels Casey's (CASY) Q1 Momentum
Per the Zacks analyst, Casey's posted solid Q1 results with a 14.2% rise in inside sales, driven by strong demand for prepared foods, bakery items, and beverages across its store network.

Restructuring Drives Solventum's (SOLV) Path to Margin Expansion
Per the Zacks analyst, Solventum's 3-phase restructuring, margin-focused plans, and $120M in savings are strengthening efficiency. The company is positioned for steady growth amid lingering headwinds

New Upgrades

Solid Data Center Demand & Expansions to Aid Equinix (EQIX)
Per the Zacks analyst, the solid demand for interconnected data center infrastructure, recurring revenue model and strategic expansions are likely to benefit Equinix.

Rising Revenues & Extensive Branch Network Aid Itau Unibanco (ITUB)
Per the Zacks analyst, steady revenue growth, along with its extensive branch network, strategic acquisitions, and technological investments, strengthens Itau Unibanco's top-line growth.

Rising Demand for ADAS & Increase in EyeQ Shipment Aid Mobileye (MBLY)
Per the Zacks analyst, the rising demand for ADAS and autonomous driving features is fueling Mobileye's prospects. The expected increase in EyeQ shipments also bolsters prospects.

New Downgrades

Drilling Activity-Slowdown to Ail SM Energy's (SM) Output
The Zacks analyst is concerned because the drop in drilling activities may cast a shadow over SM Energy's production outlook.

Higher Spending Amid Subscriber Decline Hurts Tegna (TGNA)
Per the Zacks analyst, declining subscriber growth is compelling Tegna to spend on higher programming fees and investments thereby keeping margins under pressure.

PACCAR (PCAR) Faces Global Truck Demand Slowdown & Margin Squeeze
PACCAR is seeing weaker truck demand across North America, Europe, and South America. Declining volumes and truck margin contraction make the Zacks analyst bearish on the stock.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research